Nice, France - March 23, 2022 - Iris Pharma has developed a new animal model to mimic advanced wet or exudative form of age-related macular degeneration (AMD or ARMD).
This suitable model is useful to evaluate the relative therapeutic efficacy of a compound in inhibiting retinal vascular leakage and neovascularization. It is obtained after a single intravitreal administration of the DL-α-aminoadipic acid (AAA) in rabbit, a retinal glial (Müller) cytotoxin that is known to cause glial dysfunction and death, leading to breakdown of the blood-retinal barrier and a persistent retinal neovascularization from 10-12 weeks.
The evaluation of the vascular leakage in the retina is visualized by in vivo fundus fluorescein angiography (FFA) with a slit lamp.
• Established by Iris Pharma’s research unit
• Performed in La Gaude - France, by Iris Pharma’s highly skilled and experienced staff
• Chronic model, up to 12 months
• Reproduces retinal neovascularization angiographic features like retinal neovascularization and chronic retinal vasculature leakage
